title: HCV intergenotype 2k/1b recombinant detected in a DAA-treated patient in Italy.
abstract: Direct-acting antiviral (DAA) combinations are potent and effective drugs currently recommended for treatment of chronic HCV infection. Difficult to treat genotypes are the most important predictors of treatment failure. We report a case of DAA treatment failure in an HCV-infected patient carrying a recombinant genotype 2k/1b. This strain, first isolated from a Russian patient in 2002, has now been observed for the first time in Italy.
authors.affiliation: Molecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
authors.forename: Stefania
authors.initials: S
authors.lastname: Paolucci
authors.affiliation: Molecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
authors.forename: Marta
authors.initials: M
authors.lastname: Premoli
authors.affiliation: Division of Infectious Diseases and Immunology, Department of Medical Sciences and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
authors.forename: Serena
authors.initials: S
authors.lastname: Ludovisi
authors.affiliation: Division of Infectious Diseases and Immunology, Department of Medical Sciences and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.|Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.
authors.forename: Mario U
authors.initials: MU
authors.lastname: Mondelli
authors.affiliation: Molecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.|Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.
authors.forename: Fausto
authors.initials: F
authors.lastname: Baldanti
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D000998:Antiviral Agents / Q000627:therapeutic use; D004338:Drug Combinations; D024882:Drug Resistance, Viral / Q000235:genetics*; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000145:classification / Q000187:drug effects / Q000235:genetics* / Q000254:growth & development; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D007558:Italy; D008103:Liver Cirrhosis / Q000175:diagnosis / Q000188:drug therapy* / Q000821:virology; D008875:Middle Aged; D010802:Phylogeny; D016865:Reassortant Viruses / Q000145:classification / Q000187:drug effects / Q000235:genetics* / Q000254:growth & development; D012254:Ribavirin / Q000627:therapeutic use; D017423:Sequence Analysis, RNA; D000069474:Sofosbuvir / Q000627:therapeutic use; D017211:Treatment Failure
chemical_list: D000998:Antiviral Agents; D004338:Drug Combinations; D012254:Ribavirin; D000410:Alanine Transaminase; D000069474:Sofosbuvir